|Bid||20.51 x 700|
|Ask||25.63 x 100|
|Day's Range||21.39 - 21.74|
|52 Week Range||17.68 - 22.27|
|PE Ratio (TTM)||66.69|
|Earnings Date||Feb 5, 2018 - Feb 9, 2018|
|Forward Dividend & Yield||0.24 (1.12%)|
|1y Target Est||20.60|
Myriad Genetics' (MYGN) recent collaborations are encouraging. Also, the company banks on the GeneSight and EndoPredict portfolios.
Myriad Genetics' (MYGN) tie-up with Department of VA to assess the effectiveness of GeneSight test buoys optimism. Also, favorable results might boost GeneSight's customer base
Hurricanes Harvey and Irma dealt a heavy blow to DaVita's (DVA) operating income in the third quarter. Management's tepid forecast for the full year adds to the concerns.
AUSTIN, Texas , Nov. 14, 2017 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced that management will present at the 29 th Annual Piper Jaffray Healthcare Conference to be held November ...
Divestiture of certain businesses to Cardinal Health induces year-over-year decline in Medtronic's (MDT) preliminary sales figure. However, impact of Maria is likely to be lighter on the company's finances.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Luminex Corp. Here are 5 ETFs with the largest exposure to LMNX-US. Comparing the performance and risk of Luminex Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Balanced growth across all geographical regions as well as many key life science and diagnostics product areas helps Bio-Rad (BIO) to drive the top and bottom line in Q3.
OPKO Health (OPK) posts lackluster Q3 numbers due to rising operating expenses owing to investment associated to the launch of RAYALDEE, and consistent investment in the pharmaceutical pipeline.
Globus Medical (GMED) saw its shares rise nearly 8% on the day after the company reported year-over-year growth in third-quarter earnings and revenues.
QIAGEN's (QGEN) top line continues to gain from strength in the Molecular Diagnostics space amid stiff competition and forex woes.
Phibro's (PAHC) Medicated feed additives (MFA) business was weak in the United States. Also, a persistent decline in Mineral Nutrition segment sales is likely to raise concern.
SurModics' (SRDX) stellar fourth-quarter results benefit from higher product sales, royalties, research, development and other revenues.
Continued momentum in new business generation and geographical expansions help Haemonetics (HAE) deliver strong results in Q2.